Glucagon Like Peptide 2 Receptor (GLP2R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.
The report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 2, 1, 8, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Other Diseases and Undisclosed which include indications Short Bowel Syndrome, Graft Versus Host Disease (GVHD), Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Osteoporosis, Unspecified and Unspecified Metabolic Disorders.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook